ArticleBMC cancer2019
Outcomes of orbital malignancies treated with eye-sparing surgery and adjuvant particle radiotherapy: a retrospective study.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Data-independent fluorescence molecular imaging analysis: a two-stage clustering framework for intraoperative tumor imaging.Biomedical engineering online · 2026Article
- Role of Computer-Assisted Surgery in the Management of Pediatric Orbital Tumors: Insights from a Leading Referral Center.Children (Basel, Switzerland) · 2025Article
- Long-term outcomes and prognostic factors of eye-preserving treatment with particle beam radiotherapy for orbital malignancies.BMC cancer · 2025Article
- Review of recent advances in managing periocular skin malignancies.Frontiers in oncology · 2024Review
- Comparison of the efficacy and toxicity of postoperative proton versus carbon ion radiotherapy for head and neck cancers.Annals of translational medicine · 2022Article
- Flourish of Proton and Carbon Ion Radiotherapy in China.Frontiers in oncology · 2022Review
- Orbital Metastases: A Systematic Review of Clinical Characteristics, Management Strategies, and Treatment Outcomes.Cancers · 2021Review
- Roles of skull base surgery and particle radiotherapy for orbital malignant tumors involving the skull base.Laryngoscope investigative otolaryngology · 2021Article
- Primary orbital melanoma: A report of a case and comprehensive review of the literature.Orbit (Amsterdam, Netherlands) · 2021Review
- Assessment of the Relative Biological Efficiency of Pencil Beam Scanning of Protons in Mice in Vivo.Doklady. Biochemistry and biophysics · 2021Article
- Review
- Proton beam therapy of periorbital sinonasal squamous cell carcinoma: Two case reports and review of literature.World journal of clinical oncology · 2020Article
- Evolution of Care of Orbital Tumors with Radiation Therapy.Journal of neurological surgery. Part B, Skull base · 2020Article
- Particle Beam Radiation Therapy for Skull Base Sarcomas.Frontiers in oncology · 2020Article
- Ocular, Orbital, and Adnexal Toxicity With High-dose Volumetric Modulated Arc Radiation Therapy for Orbital Malignancies.Ophthalmic plastic and reconstructive surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundTo report the clinical experience of eye sparing surgery (ESS) and adjuvant carbon-ion or proton radiotherapy (CIRT or PRT) for orbital malignancies.
methodsAn analysis of the retrospective data registry from the Shanghai Proton and Heavy Ion Center for patients with orbital tumors was conducted. The 2-year local progression-free, regional recurrence-free, distant metastasis-free, progression-free, and overall survival (LPFS, RRFS, DMFS, PFS, OS) rates as well as associated prognostic indicators were analyzed. Radiotherapy-induced acute and late toxicities were summarized.
resultsBetween 7/2014 to 5/2018, 22 patients with orbital malignancies of various pathologies received ESS followed by CIRT (18), PRT (1), or PRT + CIRT boost (3). With a median follow-up of 20.25 (range 3.8-38.8) months, the 2-year OS, PFS, LPFS, RRFS, and DMFS rates were 100, 57.9, 92.9, 93.3, and 72.8%, respectively. No acute severe (i.e., ≥grade 3) toxicity was observed. Two patients experienced severe visual impairment as late toxicities.
conclusionWith few observed acute and late toxicities, particle radiotherapy following ESS provided effective local control with infrequent severe toxicities for patients with orbital malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.